|
NZ556354A
(en)
*
|
2001-10-01 |
2008-10-31 |
Univ Virginia |
2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
|
|
GT200500281A
(es)
*
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
EP1831225A2
(en)
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
|
GB0500785D0
(en)
*
|
2005-01-14 |
2005-02-23 |
Novartis Ag |
Organic compounds
|
|
US8178509B2
(en)
*
|
2006-02-10 |
2012-05-15 |
University Of Virginia Patent Foundation |
Method to treat sickle cell disease
|
|
WO2007114926A2
(en)
|
2006-04-04 |
2007-10-11 |
The Regents Of The University Of California |
Kinase antagonists
|
|
PT2322525E
(pt)
*
|
2006-04-21 |
2013-12-26 |
Novartis Ag |
Derivados de purina para utilização como agonistas do recetor de adenosina a2a
|
|
GB0607950D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
US8188063B2
(en)
*
|
2006-06-19 |
2012-05-29 |
University Of Virginia Patent Foundation |
Use of adenosine A2A modulators to treat spinal cord injury
|
|
US7906518B2
(en)
*
|
2006-06-27 |
2011-03-15 |
Cbt Development Limited |
Therapeutic compounds
|
|
EP1889846A1
(en)
*
|
2006-07-13 |
2008-02-20 |
Novartis AG |
Purine derivatives as A2a agonists
|
|
US7985754B2
(en)
*
|
2006-07-17 |
2011-07-26 |
Trovis Pharmaceuticals, Llc |
Selective antagonists of A2A adenosine receptors
|
|
EP1903044A1
(en)
*
|
2006-09-14 |
2008-03-26 |
Novartis AG |
Adenosine Derivatives as A2A Receptor Agonists
|
|
CN101553459A
(zh)
*
|
2006-11-10 |
2009-10-07 |
诺瓦提斯公司 |
环戊烯二醇单乙酸酯衍生物
|
|
GB2467670B
(en)
|
2007-10-04 |
2012-08-01 |
Intellikine Inc |
Chemical entities and therapeutic uses thereof
|
|
US8058259B2
(en)
|
2007-12-20 |
2011-11-15 |
University Of Virginia Patent Foundation |
Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
|
|
MX2010007419A
(es)
|
2008-01-04 |
2010-11-12 |
Intellikine Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
|
EP2252293B1
(en)
|
2008-03-14 |
2018-06-27 |
Intellikine, LLC |
Kinase inhibitors and methods of use
|
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
CA2738429C
(en)
|
2008-09-26 |
2016-10-25 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
|
EP2358720B1
(en)
|
2008-10-16 |
2016-03-02 |
The Regents of The University of California |
Fused ring heteroaryl kinase inhibitors
|
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン， エルエルシー |
複素環式化合物およびその使用
|
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
|
WO2011143442A1
(en)
*
|
2010-05-12 |
2011-11-17 |
Trovis Pharmaceuticals, Llc. |
A method of treating multiple sclerosis with adenosine receptor agonists
|
|
CA2799579A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
|
US20130324461A1
(en)
*
|
2010-08-26 |
2013-12-05 |
Michail V. Sitkovsky |
Methods and compositions for preventing or treating obesity
|
|
RU2013114767A
(ru)
*
|
2010-09-29 |
2014-11-10 |
СК Биофармасьютикалз Ко., Лтд. |
Новые производные метилциклогексана и его применение
|
|
JP2013545749A
(ja)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
複素環化合物及びその使用
|
|
WO2012075381A1
(en)
|
2010-12-03 |
2012-06-07 |
Epizyme, Inc. |
Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
|
|
US9145438B2
(en)
|
2010-12-03 |
2015-09-29 |
Epizyme, Inc. |
7-deazapurine modulators of histone methyltransferase, and methods of use thereof
|
|
ES2637113T3
(es)
|
2011-01-10 |
2017-10-10 |
Infinity Pharmaceuticals, Inc. |
Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
|
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
|
US9132131B2
(en)
|
2011-04-21 |
2015-09-15 |
Saint Louis University |
Use of adenosine A3 receptor agonists for treatment of neuropathic pain
|
|
HK1198443A1
(en)
|
2011-07-19 |
2015-04-24 |
无限药品股份有限公司 |
Heterocyclic compounds and uses thereof
|
|
AR088218A1
(es)
|
2011-07-19 |
2014-05-21 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos utiles como inhibidores de pi3k
|
|
MX2014002542A
(es)
|
2011-08-29 |
2014-07-09 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos.
|
|
CA2846496C
(en)
|
2011-09-02 |
2020-07-14 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
|
CN104363757B
(zh)
*
|
2012-02-11 |
2017-05-24 |
中央研究院 |
治疗疼痛的方法及组合物
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
WO2014026198A1
(en)
|
2012-08-10 |
2014-02-13 |
Epizyme, Inc. |
Inhibitors of protein methyltransferase dot1l and methods of use thereof
|
|
US9597348B2
(en)
|
2012-09-06 |
2017-03-21 |
Epizyme, Inc. |
Method of treating leukemia
|
|
JP2015532287A
(ja)
|
2012-09-26 |
2015-11-09 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ｉｒｅ１の調節
|
|
AU2013337717B2
(en)
|
2012-11-01 |
2018-10-25 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using PI3 kinase isoform modulators
|
|
JP2016517426A
(ja)
|
2013-03-15 |
2016-06-16 |
エピザイム，インコーポレイティド |
置換プリン化合物の合成方法
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
PT3052485T
(pt)
|
2013-10-04 |
2021-10-22 |
Infinity Pharmaceuticals Inc |
Compostos heterocíclicos e suas utilizações
|
|
MX382033B
(es)
|
2014-03-19 |
2025-03-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2017048702A1
(en)
|
2015-09-14 |
2017-03-23 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
WO2017160930A1
(en)
*
|
2016-03-16 |
2017-09-21 |
Kalyra Pharmaceuticals, Inc. |
Analgesic compounds
|
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
SG11201811237WA
(en)
|
2016-06-24 |
2019-01-30 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
|
CA3033867A1
(en)
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
US11597744B2
(en)
|
2017-06-30 |
2023-03-07 |
Sirius Therapeutics, Inc. |
Chiral phosphoramidite auxiliaries and methods of their use
|